menu
    • menu

    Company profile for Allergan Aesthetics

    Abbvie Contract Manufacturing-PSE
    News
    Allergan Aesthetics To Launch Three New Training Centers In US

    12 Feb 2025

    // PR NEWSWIRE

    Allergan, ASPS, Aesthetic Society Release Videos for Women Surgeons

    05 Feb 2025

    // PR NEWSWIRE

    Allergan's AA Signature Program Unveiled At IMCAS 2025 Congress

    24 Jan 2025

    // PR NEWSWIRE

    DATA COMPILATION
    #PharmaFlow

    abbvie VB RM

    Contact Supplier

    Website

    Bio-Europe Spring

    Not Confirmed

    Book a meeting

    envelop Contact Supplier

    Latest Content by PharmaCompass

    radio-compass-blog/ai-drug-discovery-market-to-grow-30-cagr-to-reach-us-35-bn-by-2034-novo-lilly-bms-forge-deals

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    INSPECTIONS & REGISTRATIONS

    PharmaCompass
    Related CompaniesRelated Companies

    About

    We create the products and technologies that drive the advancement of aesthetic medicine. At Allergan Aesthetics, an AbbVie company, we develop, manufacture, and market a portfolio of leading aesthetics brands and products. Our aesthetics portfolio includes facial injectables, body contouring, plastics, skin care, and more. With our own research and development team focused on driving innovation in aesthetics, we’re committed to providing the most comprehensive science-based product offerings available.

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Allergan AestheticsUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    Irvine, California
    Telephone
    Telephone
    +1 800 377-7790
    Client Email
    Email
    abbviecontractmfg@abbvie.com
    Client Website
    Website
    https://www.allerganaesthetics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/allergan-aesthetics/
    youtube
    YouTube
    Twitter
    Twitter
    Contact Info
    Others

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    Default Event

    DCAT Week

    Not Confirmed

    envelop Contact Supplier

    DCAT Week

    Post an Enquiry

    Meeting

    Digital content read-more

    Explore the latest content creation from this company

    NEWS #PharmaBuzz

    read-more
    read-more
    Allergan Aesthetics To Launch Three New Training Centers In US
    Allergan Aesthetics To Launch Three New Training Centers In US

    12 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/allergan-aesthetics-to-launch-three-new-state-of-the-art-training-centers-in-the-us-expanding-access-to-high-quality-aesthetics-training-302374118.html

    PR NEWSWIRE
    12 Feb 2025
    Share Share
    Allergan, ASPS, Aesthetic Society Release Videos for Women Surgeons
    Allergan, ASPS, Aesthetic Society Release Videos for Women Surgeons

    05 Feb 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/allergan-aesthetics-the-american-society-of-plastic-surgeons-asps-and-the-aesthetic-society-release-two-new-engaging-limitless-videos-celebrating-women-surgeons-302368870.html

    PR NEWSWIRE
    05 Feb 2025
    Share Share
    Allergan's AA Signature Program Unveiled At IMCAS 2025 Congress
    Allergan's AA Signature Program Unveiled At IMCAS 2025 Congress

    24 Jan 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/allergan-aesthetics-unveils-new-aa-signature-program-and-immersive-booth-at-imcas-world-congress-2025-302359301.html

    PR NEWSWIRE
    24 Jan 2025
    Share Share
    Allergan Aesthetics Offers Free Business Education Online
    Allergan Aesthetics Offers Free Business Education Online

    18 Nov 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/allergan-aesthetics-offers-free-business-education-courses-online-to-support-growing-practices-with-allergan-aesthetics-products-302307919.html

    PR NEWSWIRE
    18 Nov 2024
    Share Share
    SkinSpirit join Allergan Aesthetics in Empowering New Gen. of Women
    SkinSpirit join Allergan Aesthetics in Empowering New Gen. of Women

    30 Oct 2024

    // PRESS RELEASE

    https://news.abbvie.com/2024-10-29-SkinSpirit-joins-Allergan-Aesthetics-in-Supporting-Girls-Inc-and-Empowering-the-New-Generation-of-Women-in-STEM#:~:text=IRVINE%2C%20Calif.%2C%20Oct.,explore%20career%20paths%20in%20STEM

    PRESS RELEASE
    30 Oct 2024
    Share Share
    SkinSpirit Joins Allergan In Supporting Girls Inc. STEM Initiative
    SkinSpirit Joins Allergan In Supporting Girls Inc. STEM Initiative

    29 Oct 2024

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/skinspirit-joins-allergan-aesthetics-in-supporting-girls-inc-and-empowering-the-new-generation-of-women-in-stem-302289495.html

    PR NEWSWIRE
    29 Oct 2024
    Share Share

    Drugs in Development

    read-more
    read-more
    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of TrenibotulinumtoxinE (BoNT/E) for the Treatment of Glabellar ...

    Details:

    AGN-151586 (trenibotulinumtoxinE) is a first-in-class, short-acting neurotoxin, which is investigated for the treatment of Glabellar Lines. If approved, BoNT/E will be the first neurotoxin of its kind available to patients.


    Lead Product(s): TrenibotulinumtoxinE

    Therapeutic Area: Dermatology Brand Name: AGN-151586

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable October 24, 2023

    Abbvie CB

    01

    Allergan Aesthetics

    U.S.A
    arrow
    Bacteriophage Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : TrenibotulinumtoxinE

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Allergan Aesthetics Announces Positive Topline Results from Two Pivotal Phase 3 Studies of Trenibo...

    Details : AGN-151586 (trenibotulinumtoxinE) is a first-in-class, short-acting neurotoxin, which is investigated for the treatment of Glabellar Lines. If approved, BoNT/E will be the first neurotoxin of its kind available to patients.

    Product Name : AGN-151586

    Product Type : Large molecule

    Upfront Cash : Not Applicable

    October 24, 2023

    Abbvie CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of OnabotulinumtoxinA (BOTOX® Cosmetic) for the Treatment of Platysma ...

    Details:

    Botox Cosmetic (onabotulinumtoxinA) is first and only product of its kind that is approved by U.S. FDA to treat three areas, temporarily improving the appearance of moderate to severe forehead lines, glabellar lines and crow's feet in adults.


    Lead Product(s): OnabotulinumtoxinA

    Therapeutic Area: Dermatology Brand Name: Botox Cosmetic

    Study Phase: Phase IIIProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 18, 2023

    Abbvie CB

    02

    Allergan Aesthetics

    U.S.A
    arrow
    Bacteriophage Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : OnabotulinumtoxinA

    Therapeutic Area : Dermatology

    Highest Development Status : Phase III

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Allergan Aesthetics Announces Positive Topline Results from Second Phase 3 Study of Onabotulinumto...

    Details : Botox Cosmetic (onabotulinumtoxinA) is first and only product of its kind that is approved by U.S. FDA to treat three areas, temporarily improving the appearance of moderate to severe forehead lines, glabellar lines and crow's feet in adults.

    Product Name : Botox Cosmetic

    Product Type : Large molecule

    Upfront Cash : Not Applicable

    September 18, 2023

    Abbvie CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    JUVÉDERM® VOLUX™ XC For Improvement Of Jawline Definition Now Available Nationwide

    Details:

    Juvederm Voluma™ XC (hyaluronic acid) is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face in adults over the age of 21.


    Lead Product(s): Hyaluronic Acid

    Therapeutic Area: Dermatology Brand Name: Juvederm Volux XC

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 18, 2023

    Abbvie CB

    03

    Allergan Aesthetics

    U.S.A
    arrow
    Bacteriophage Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Hyaluronic Acid

    Therapeutic Area : Dermatology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    JUVÉDERM® VOLUX™ XC For Improvement Of Jawline Definition Now Available Nationwide

    Details : Juvederm Voluma™ XC (hyaluronic acid) is indicated for deep (subcutaneous and/or supraperiosteal) injection for cheek augmentation to correct age-related volume deficit in the mid-face in adults over the age of 21.

    Product Name : Juvederm Volux XC

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    January 18, 2023

    Abbvie CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    SkinMedica® Launches Even & Correct

    Details:

    The SkinMedica (coffea arabica) Even & Correct products are hydroquinone-free, well tolerated, and effective on all skin types and for multiple ethnicities. Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product.


    Lead Product(s): Coffea Arabica,Caffeine,Hydrolyzed Rice Protein

    Therapeutic Area: Dermatology Brand Name: SkinMedica

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable January 17, 2023

    Abbvie CB

    04

    Allergan Aesthetics

    U.S.A
    arrow
    Bacteriophage Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Coffea Arabica,Caffeine,Hydrolyzed Rice Protein

    Therapeutic Area : Dermatology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    SkinMedica® Launches Even & Correct

    Details : The SkinMedica (coffea arabica) Even & Correct products are hydroquinone-free, well tolerated, and effective on all skin types and for multiple ethnicities. Most SkinMedica® products are intended to meet the FDA's definition of a cosmetic product.

    Product Name : SkinMedica

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    January 17, 2023

    Abbvie CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Allergan Aesthetics Celebrates Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day

    Details:

    BOTOX (OnabotulinumtoxinA) Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults.


    Lead Product(s): OnabotulinumtoxinA

    Therapeutic Area: Dermatology Brand Name: Botox

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable November 02, 2022

    Abbvie CB

    05

    Allergan Aesthetics

    U.S.A
    arrow
    Bacteriophage Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : OnabotulinumtoxinA

    Therapeutic Area : Dermatology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Allergan Aesthetics Celebrates Fourth Annual BOTOX® Cosmetic (onabotulinumtoxinA) Day

    Details : BOTOX (OnabotulinumtoxinA) Cosmetic is a prescription medicine that is injected into muscles and used to temporarily improve the look of moderate to severe forehead lines, crow's feet lines, and frown lines between the eyebrows in adults.

    Product Name : Botox

    Product Type : Large molecule

    Upfront Cash : Not Applicable

    November 02, 2022

    Abbvie CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign Cast, Spotlighting 25 Real People and Their Stories

    Details:

    BOTOX® Cosmetic (onabotulinumtoxinA) is first and only product of its kind that is approved by U.S. FDA to treat three areas, temporarily improving the appearance of moderate to severe forehead lines, glabellar lines and crow's feet in adults.


    Lead Product(s): OnabotulinumtoxinA

    Therapeutic Area: Dermatology Brand Name: Botox

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable September 13, 2022

    Abbvie CB

    06

    Allergan Aesthetics

    U.S.A
    arrow
    Bacteriophage Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : OnabotulinumtoxinA

    Therapeutic Area : Dermatology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Allergan Aesthetics and BOTOX® Cosmetic (OnabotulinumtoxinA) Reveal New 'See Yourself' Campaign C...

    Details : BOTOX® Cosmetic (onabotulinumtoxinA) is first and only product of its kind that is approved by U.S. FDA to treat three areas, temporarily improving the appearance of moderate to severe forehead lines, glabellar lines and crow's feet in adults.

    Product Name : Botox

    Product Type : Large molecule

    Upfront Cash : Not Applicable

    September 13, 2022

    Abbvie CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 2022 Conference

    Details:

    Data analyses of onabotulinumtoxinA (BOTOX®) in adult patients with chronic migraine, cervical dystonia, overactive bladder, spasticity, and pediatric patients with neurogenic detrusor overactivity provide further insights on real-world utilization and long-term use.


    Lead Product(s): OnabotulinumtoxinA

    Therapeutic Area: Neurology Brand Name: Botox

    Study Phase: ApprovedProduct Type: Large molecule

    Recipient: AbbVie Inc

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 25, 2022

    Abbvie CB

    07

    Allergan Aesthetics

    U.S.A
    arrow
    Bacteriophage Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : OnabotulinumtoxinA

    Therapeutic Area : Neurology

    Highest Development Status : Approved

    Recipient : AbbVie Inc

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    AbbVie and Allergan Aesthetics to Present New Data from Leading Neurotoxin Portfolio at TOXINS 202...

    Details : Data analyses of onabotulinumtoxinA (BOTOX®) in adult patients with chronic migraine, cervical dystonia, overactive bladder, spasticity, and pediatric patients with neurogenic detrusor overactivity provide further insights on real-world utilization and ...

    Product Name : Botox

    Product Type : Large molecule

    Upfront Cash : Not Applicable

    July 25, 2022

    Abbvie CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Allergan, an AbbVie Company, to Present New Data from its Leading Portfolio of Eye Care Treatments at the 2022 Association for Research in Vision and Op...

    Details:

    VUITY, an optimized formulation of pilocarpine, established eye care therapeutic, specifically designed to treat age-related blurry near vision. It is delivered with proprietary pHast™ technology, which allows VUITY to rapidly adjust to physiologic pH of the tear film.


    Lead Product(s): Pilocarpine Hydrochloride

    Therapeutic Area: Ophthalmology Brand Name: Vuity

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 28, 2022

    Abbvie CB

    08

    Allergan Aesthetics

    U.S.A
    arrow
    Bacteriophage Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pilocarpine Hydrochloride

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Allergan, an AbbVie Company, to Present New Data from its Leading Portfolio of Eye Care Treatments...

    Details : VUITY, an optimized formulation of pilocarpine, established eye care therapeutic, specifically designed to treat age-related blurry near vision. It is delivered with proprietary pHast™ technology, which allows VUITY to rapidly adjust to physiologic pH ...

    Product Name : Vuity

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    April 28, 2022

    Abbvie CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) Ann...

    Details:

    VUITY is an optimized formulation of pilocarpine, an established eye care therapeutic, specifically designed to treat age-related blurry near vision. It is delivered with proprietary pHas technology, which allows VUITY to rapidly adjust to physiologic pH of the tear film.


    Lead Product(s): Pilocarpine Hydrochloride

    Therapeutic Area: Ophthalmology Brand Name: Vuity

    Study Phase: ApprovedProduct Type: Small molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 19, 2022

    Abbvie CB

    09

    Allergan Aesthetics

    U.S.A
    arrow
    Bacteriophage Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Pilocarpine Hydrochloride

    Therapeutic Area : Ophthalmology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    Allergan, an AbbVie Company, to Present New Data from its Eye Care Portfolio at the 2022 American ...

    Details : VUITY is an optimized formulation of pilocarpine, an established eye care therapeutic, specifically designed to treat age-related blurry near vision. It is delivered with proprietary pHas technology, which allows VUITY to rapidly adjust to physiologic pH...

    Product Name : Vuity

    Product Type : Small molecule

    Upfront Cash : Not Applicable

    April 19, 2022

    Abbvie CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    • Development Update
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval

    Details:

    BOTOX Cosmetic (onabotulinumtoxinA), the first and only neurotoxin product approved by U.S.FDA, to temporarily improve the look of moderate to severe lines in three areas; frown lines, crow's feet and forehead lines.


    Lead Product(s): OnabotulinumtoxinA

    Therapeutic Area: Dermatology Brand Name: Botox

    Study Phase: ApprovedProduct Type: Large molecule

    Sponsor: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 13, 2022

    Abbvie CB

    10

    Allergan Aesthetics

    U.S.A
    arrow
    Bacteriophage Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : OnabotulinumtoxinA

    Therapeutic Area : Dermatology

    Highest Development Status : Approved

    Partner/Sponsor/Collaborator : Not Applicable

    Deal Size : Not Applicable

    Deal Type : Not Applicable

    DEALS_DEV arrow-down

    BOTOX® Cosmetic (onabotulinumtoxinA) Celebrates 20 Years Since First U.S. FDA Approval

    Details : BOTOX Cosmetic (onabotulinumtoxinA), the first and only neurotoxin product approved by U.S.FDA, to temporarily improve the look of moderate to severe lines in three areas; frown lines, crow's feet and forehead lines.

    Product Name : Botox

    Product Type : Large molecule

    Upfront Cash : Not Applicable

    April 13, 2022

    Abbvie CB

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    Only 10 entries up to this point, click to access all click full view read-more
    click full view
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

    Inspections and registrations

    Check the inspections & registration from this company

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search